Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials.

Spasticity is characterized by increased muscle stiffness and spasms, which can be uncomfortable and hinder movement.

Jazz Pharmaceuticals' Study

The study, funded by GW Pharmaceuticals (now part of Jazz Pharmaceuticals) (NASDAQ: JAZZ), the developer of Nabiximols, showed that oral spray therapy led to a reduction in spasticity symptoms and daily muscle spasm counts among participants.

Nabiximols, marketed as Sativex, is approved for treating MS-related spasticity in …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.